CD59

GWB-E738D1

966

MEM-43/5

Phosphate buffered saline

Use 10ul of the suggested working dilution to label 106 cells in 100ul. Suggested

Potent inhibitor of the complement membrane attack complex (MAC) action. Acts by binding to the C8 and/or C9 complements of the assembling MAC thereby preventing incorporation of the multiple copies of C9 required for complete formation of the osmolytic pore. This inhibitor appears to be species-specific. Involved in signal transduction for T-cell activation complexed to a protein tyrosine kinase.

Interacts with T-cell surface antigen CD2.

N- and O-glycosylated. The N-glycosylation mainly consists of a family of biantennary complex-type structures with and without lactosamine extensions and outer arm fucose residues. Also significant amounts of triantennary complexes (22%). Variable sialylation also present in the Asn-43 oligosaccharide. The predominant O-glycans are mono-sialylated forms of the disaccharide Gal-beta-1 3GalNAc and their sites of attachment are probably on Thr-76 and Thr-77. The GPI-anchor of soluble urinary CD59 has no inositol-associated phospholipid but is composed of seven different GPI-anchor variants of one or more monosaccharide units. Major variants contain sialic acid mannose and glucosamine Sialic acid linked to an N-acetylhexosamine-galactose arm is present in two variants.

Contains 1 UPAR/Ly6 domain. 1. Stefanova. I. et al. (1989) Characterization of a broadly expressed human leucocyte surface antigen MEM-43 anchored in membrane through phosphatidylinositol Mol. Immunol. 26: 153-161. 2. Stefanova. I. . et al. (1989) in Leucocyte Typing IV: White cell differentiation antigens. Ed. Knapp. W. et al. Oxford University Press pp 678-697. 3. Tandon. N. et al. (1994) Expression and function of multiple regulators of complement activation in autoimmune thyroid disease. 4. Horejsi. V. et al. (1988) Monoclonal antibodies against human leucocyte antigens. II. Antibodies against CD45 (T200). CD3 (T3). CD43. CD10 (CALLA). transferrin receptor (T9). a novel broadly expressed 18-kDa antigen (MEM-43) and a novel antigen of restricted expression (MEM-74). 5. Horejsi. V. et al. (1988) Title Fol. Bio. (Prague) 34: 23-24.